Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials

Medicine (United States)

Volumn 96, Issue 26, 2017, Pages

  Hao, Chunyan ^a,b   Tian, Jinhui ^a   Liu, Huiling ^c,d   Li, Fei ^a,b   Niu, Hongxia ^a,b   Zhu, Bingdong ^a,b  

^a Gansu Provincial Key Laboratory of Evidence Based Medicine and Clinical Translation   (China)

^b LANZHOU UNIVERSITY   (China)

^c GANSU PROVINCIAL HOSPITAL   (China)

^d Institute of Pathogen Biology   (China)

Author keywords

anti CTLA 4; anti PD 1; immunotherapy; ipilimumab; melanoma; nivolumab; pembrolizumab

Indexed keywords

IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MELANOMA; MONOTHERAPY; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SURVIVAL RATE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; META ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85021703862     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007325     Document Type: Review

References (38)

1. Aris M, Barrio MM. Combining immunotherapy with oncogenetargeted therapy: a new road for melanoma treatment. Front Immunol 2015;6:46
2. Faghfuri E, Faramarzi MA, Nikfar S, et al. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Rev Anticancer Ther 2015;15: 981-93
3. Mashima E, Inoue A, Sakuragi Y, et al. Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther 2015;8:2045-51
4. Mahoney KM, Freeman GJ, McDermott DF. The next immunecheckpoint inhibitors: PD-1/PD-L1 blockade in melanoma clinical therapeutics. Clin Ther 2015;37:764-82
5. Carosella ED, Ploussard G, LeMaoult J, et al. A systemic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/P D-L1, and HLA-G. Eur Urol 2015;68:267-79
6. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infitrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104: 3360-5
7. Nakanishi J, Wada Y, Matsumoto K, et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007;56:1173-82
8. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757-66
9. Massi D, Brusa D, Merelli B, et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol 2014;25:2433-42
10. Barbee MS, Ogunniyi A, Horvat TZ, et al. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015;49: 907-37
11. Niezgoda A, Niezgoda P, Czajkowski R. Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy. Biomed Res Int 2015;2015:851387
12. Pardoll DM. The blockade of immunecheck points in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
13. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
14. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364: 2517-26
15. Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107:4275-80
16. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-54
17. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30
18. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369: 134-44
19. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30
20. Weber JS, D Angelo S, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84
21. Weber J, Minor D, D Angelo S, et al. Overall survival in patients with advanced melanoma (MEL) who received nivolumab (NIVO) versus investigators choice chemotherapy (ICC) in the phase 3 CheckMate 037 trial. Pigment Cell Melanoma Res 2017;30:150
22. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34
23. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL). Ann Oncol 2015;26:vi28
24. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372: 2006-17
25. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016;17:1558-68
26. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32
27. Long G,McNeill C, Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006. Asia-Pacific J Clin Oncol 2016;12:61
28. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-18
29. Hamid O, Puzanov I, Dummer R, et al. Final overall survival for KEYNOTE-002: Pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Ann Oncol 2016;27(suppl 6):1107O
30. Chen R, Peng PC, Wen B, et al. Anti-Programmed cell death (PD)-1 immunotherapy for malignant tumor: a systematic review and metaanalysis. Transl Oncol 2016;9:32-40
31. Yun S, Vincelette ND, Green MR, et al. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 2016;5:1481-91
32. Jin C, Zhang X, Zhao K, et al. The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. Onco Targets Ther 2016;9:1571-8
33. Lin Z, Chen X, Li Z, et al. PD-1 antibody monotherapy for malignant melanoma: a systematic review and meta-analysis. PLoS One 2016;11: e0160485
34. GuanX,WangH,Ma F, et al. The efficacy and safety of programmed cell death 1 and programmed cell death 1 ligand inhibitors for advanced melanoma: a meta-analysis of clinical trials following the PRISMA guidelines. Medicine 2016;95:e3134
35. Tie Y, Ma X, Zhu C, et al. Safety and efficacy of nivolumab in the treatment of cancers: ameta-analysis of 27 prospective clinical trials. Int J Cancer 2017;140:948-58
36. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration. Updated March 2011
37. Homet Moreno B, Parisi G, Robert L, et al. Anti-PD-1 therapy in melanoma. Semin Oncol 2015;42:466-73
38. Weber JF, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016;17:943-55